Ischemic preconditioning (IP) is a phenomenon that organs develop a tolerance toward subsequent lethal ischemic insults. Among the factors that are involved in IP, IL-1β and its endogenous receptor antagonist IL-1ra have been identified as important players in the induction of IP. The present study investigated whether IP affects the levels of these two antagonistic proteins during tolerance and reperfusion periods after ischemic stroke. The IP 24 h prior to ischemic stroke resulted in neuroprotection in the cortex. IP-induced protection is accompanied by increased IL-1β gene and IL-1ra gene and protein levels during the tolerance period. In the post-ischemic cortex, IP resulted in the suppression of IL-1β mRNA and protein levels at 6 h without affecting IL-1ra expression and the up-regulation of IL-1ra protein at 24 h. These findings demonstrate that IP differentially regulates cortical IL-1β and IL-1ra expression before and after ischemic stroke and suggest that the shift toward an anti-inflammatory state in the post-ischemic cortex may contribute to IP-induced neuroprotection.
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Introduction
Ischemic preconditioning (IP) triggered by a sub-lethal stimulus induces tissue tolerance toward subsequent full insult through modulation of endogenous molecules (Swain et al., 1984; Murry et al., 1986; Dirnagl et al., 1999; Gidday, 2006) . The IP-induced protective effect against ischemic and reperfusion injuries has been demonstrated in a variety of organs including heart, lung, liver and brain (Kitagawa et al., 1990; Barrier et al., 2005; Cho et al., 2005; Pasupathy and HomerVanniasinkam, 2005) . In the brain, brief global or focal ischemic stimuli several minutes to hours before serious ischemic injury attenuate neuronal cell death and infarct volumes in animal models of stroke (Ohtsuki et al., 1996; Barone et al., 1998; Cho et al., 2005) . Although multiple protective mechanisms involving neurotransmitters, kinases, transcription factors and cytokines have been suggested for the induction of ischemic tolerance, the molecular mechanism that governs IP-induced neuroprotection and effector modules that account for the protection are not fully defined (Kirino, 2002; Dirnagl et al., 2003; Dirnagl and Meisel, 2008) .
Interleukin-1β (IL-1β), a pro-inflammatory cytokine, has been implicated in ischemic brain injury. For instance, exogenous administration of IL-1β increases brain injury while immunoneutralization of IL-1β reduces ischemic brain damages (Yamasaki et al., 1995; Loddick and Rothwell, 1996) . The role of IL-1β in ischemic brain is further supported by showing that its endogenous receptor antagonist (IL-1ra), which blocks IL-1 mediated signaling, was neuroprotective (Relton and Rothwell, 1992; Betz et al., 1995) . Literature shows that exogenous administration of IL-1ra or overexpression of IL-1ra gene in mice is protective in cerebral ischemia (Relton and Rothwell, 1992; Betz et al., 1995) and deletion of the IL-1ra gene was shown to increase neuronal injury (Pinteaux et al., 2006) . These studies suggest that repression of IL-1β and/or increase of IL-1ra can be a useful therapeutic target for ischemic stroke.
In spite of the contributing role of IL-1β in ischemic injury, low levels of IL-1β are reported to play a key role in the induction of ischemic tolerance. A study showed that global IP in gerbil increased IL-1β levels in the blood and that systemic IL-1β administration prior to ischemia protected CA1 neurons, which disappeared by coadministration of IL-1ra (Ohtsuki et al., 1996) . Similarly, a preconditioning by brief (15 min) middle cerebral artery occlusion (MCAO) in spontaneously hypertensive rats induced low-level IL-β expression in the cortex during the tolerance period, indicating a contribution to ischemic tolerance by IL-1β (Wang et al., 2000) . In the same model, Barone et al. (1998) reported an increase in IL-1ra expression in the cortex during the tolerance period. Considering that IL-1ra blocks biological activity of IL-1β, it is difficult to address the roles for these Journal of Neuroimmunology 217 (2009) 14-19 
